Azathioprine is commonly used in Crohn's disease. It has been administered to many pregnant women over many years without significant side effects. However, pancytopenia and severe combined immune deficiency-like disease have been reported in infants whose mothers received azathioprine throughout pregnancy. Moreover, myelotoxicity has been described in patients being treated with azathioprine and having a low or absent thiopurine S-methyl transferase [TPMT] activity. Here, we describe the case of a newborn girl found to be highly lymphopenic [< 300 CD3+ T cells] after a positive newborn screening for severe combined immuno deficiency. The clinical examination was normal. The mother was treated with azathioprine throughout her pregnancy, without any reduction of the dose. It was shown that the mother was heterozygous for the 3A [TPMT] activity mutation and that the baby was homozygous for the same mutation; 6-thioguanine nucleotides were high (744 pmol/8.10
Introduction
Azathioprine [AZA] is commonly used for the treatment of active inflammatory bowel disease [IBD], Crohn's disease [CD] , and ulcerative colitis [UC] , because of its immunosuppressive and cytotoxic properties. AZA is a prodrug, rapidly cleaved to 6-mercaptopurine after ingestion, probably by glutathione S-transferase. 1 6-MP, inactive by itself, is metabolised in both liver and gut by three competitive enzymes: thiopurine S-methyl-transferase [TPMT] , catalysing 6-MP to inactive 6-methyl-MP ; xanthine oxidase [XO] , catalysing 6-MP to inactive thiouric acid; and hypoxanthine guanine phosphoribosyltransferase [HGPRT] , converting 6-MP to active 6-thiogunine nucleotides . The TPMT gene is subject to genetic polymorphism, and then is responsible for a variable enzyme activity contributing to a variation in active metabolite concentrations and also to the inter-individual response to AZA treatment. A low TPMT enzyme activity can lead to an increase in 6-TGN metabolites that have been associated with myelotoxicity. 2 In Caucasians and Americans, about 10% of the population inherit one non-functional TPMT allele [heterozygous] conferring an intermediate TPMT activity, and 0.3% inherit two non-functional alleles [homozygous] conferring absent or low activity. 3 TPMT genotyping and/or phenotyping and intra-erythrocyte TGN measurement allow individualised AZA dosage to prevent toxicity and improve efficacy.
During pregnancy, AZA is recommended to avoid relapse of the mother's IBD disease and flares, which increase the risk of preterm birth and low birthweight. 4, 5 It has been shown that AZA does not increase the risk of major congenital anomaly in children, 6 ,7 the rate of pregnancy and neonatal complications, or the rate of unfavourable pregnancy outcome in the mother and the newborn. 8 However, a risk of preterm birth and low birthweight during pregnancy has been described, 9 and a few cases of infant myelotoxicity, neonatal infections, severe combined immunodeficiency [SCID] , and hypogammaglobulinaemia in newborns have also been reported. 10 Here, we describe the case of a baby with a profound lymphopenia discovered after a positive test for neonatal screening for SCID [DEPISTREC study clinical trial N°NCT02244450]. 11 Her mother was being treated with 100 mg/day AZA throughout her pregnancy.
Case Report and Results

Maternal history
A case of CD was diagnoseded a few years ago, requiring AZA treatment. AZA 100 mg was continued daily throughout pregnancy, without any modification. TPMT genotyping and 6-TGN measurement were not performed before or during pregnancy. Nothing abnormal was noted during the pregnancy. At Day 37 after delivery, and because of the discovery of the child's lymphopenia, the AZA metabolites were measured and TPMT genotype identified. The results showed high values for 6-TGN [744 pmol/8.10
8 red blood cells and a heterozygous 3A TPMT genotype]. The dosage of AZA was then adapted during a consultation with a gastroenterologist.
Child history
The patient is a first child born at 38 weeks of gestation, with normal size on delivery [weight: 2780 g, length: 50. 5 11 was offered to the parents. After approval with a signed consent from the parents, TRECs [T-cell receptor excision circles] quantification was performed at Day 10 and showed no TRECs, suggesting a profound lymphopenia. According to the protocol, she was referred to the local paediatrician in charge of primary immunodeficiencies. At admission on Day 13, she was clinically well. The following laboratory results were obtained: haemoglobin: 16.2 g/dl, neutrophils: 1.07 Giga/L, lymphocytes: 0.2 Giga/L. Complementary analyses showed a profound T, B, and NK lymphopenia, mimicking an SCID. Lymphocyte counts and TRECs analysis were regularly assessed, until normalisation [ Table 1 and Figure 1 ]. Because of the mother's AZA treatment, 6-TGN and 6-MMP nucleotides were quantified at Day 37 and showed the presence of 6-TGN in the baby [177 pmol/8.10
8 RBC] with no 6-MMP nucleotides. Then TPMT genotyping was performed and showed that she was homozygous for two mutations (c.460G > A[p.Ala154Thr] exon 6; c.719A > G[p.Tyr240Cys] exon 9), therefore homozygous for the 3A TPMT genotype.
Consequently, prophylaxis using trimethoprim-sulphamethoxazole was started at the age of 1 month of life [25 mg/kg sulphamethoxazole t3 days per week]. Home isolation was recommended. The clinical course remained satisfactory, with regular weight gain and good psychomotor development. At 3 months of life, the biological balance normalised, the 6-TGN became undetectable and the prophylactic treatment was stopped. Monitoring at the paediatric unit was also stopped.
Discussion
It has been shown that low TPMT activity is associated with increased 6-TGN metabolites and a risk of myelotoxicity. The incorporation of 6-TGN into DNA causes apoptosis, and inhibits the proliferation of lymphocytes.
We describe here a fortuitous discovery of a deep and prolonged lymphopenia in a 13-day old infant, whose mother was treated with ADA, adenosine deaminase; BTA, bêta actine; d, Day; Hb, haemoglobin; 6-MMP, 6-methylmercaptopurine nucleotides; PNP, purine nucléoside phophorylase; RBC, RBC, red blood cells; 6-TGN, 6-thioguanine nucleotides; TRECs, T-cell receptor excision circles AZA during pregnancy. The baby was clinically well. Lymphocyte blood counts normalised on Day 71. After studying the history of the pregnancy, 6-TGN were measured at Day 37 in the infant, which showed the presence of 6-TGN─suggesting an iatrogenic aetiology of the lymphopenia. TPMT genotyping showed that the mother had intermediate TPMT activity and the infant had very low or absent TPMT activity. As the lymphopenia was severe, the baby was subsequently treated with the trimethoprim-sulphamethoxazole and did not develop any infection.
Several cases of AZA-induced myelotoxicy in newborns have been published [ Table 2 ]. The first case, published in 1974, was an infant whose mother was treated by AZA and prednisone throughout pregnancy. 12 The baby was lymphopenic and IgG were reduced. He recovered from both by 10 weeks of age. The second case 13 was fatal, showing the importance of the diagnosis: a preterm boy, whose mother received 125 mg AZA and 12.5 mg prednisone daily throughout pregnancy, presented at birth with a severe immunodeficiency and died at Day 28 after serious infections. Maruyama et al. 14 reported a case of pancytopenia where 6-TGN were very high at Day 3 [1480 pmol/8.10
8 red blood cells] but the lymphocyte blood count was restored at Day 50. In our case, the concentrations of 6-TGN were not measured at the delivery, but the analysis at Day 37 showed that the baby had been exposed to 6-TGN. The decrease of the 6-TGN that followed correlated to the increase of the lymphocyte count. Unquestionably, high 6-TGN in the baby was due to high 6-TGN on the mother. Nevertheless, the question of the status of the child's TPMT enzyme arises.
The Food and Drug Administration [FDA] recommends that AZA should not be given during pregnancy without careful weighing of risk versus benefit; and whenever possible, AZA should be avoided. Before the use of AZA, the FDA recommends giving consideration to the genotype or phenotype of TPMT [http://dailymed. nlm.nih.gov]. In Europe, the ECCO [European Crohn and Colitis Organisation] consensus on reproduction and pregnancy in IBD considers that thiopurines present a low risk during pregnancy, but mentions that a few cases of immunological and haematological abnormalities have been observed in newborns. 15 TPMT genotyping or phenotyping was not recommended, nor stemming dose decrease. Nevertheless, in France, the summary of product characteristics advises reducing the dose of AZA in pregnant women, if possible, in order to avoid leukopenia and thrombocytopenia. In each case, a blood count and formula should be carried out at birth for the infant. However, this analysis is not always carried out, sometimes because the obstetrician has not the information about AZA treatment. The present case report also demonstrates the importance of collaboration between physicians, obstetricians, and gastroenterologists, for the treatment of IBD in pregnant women.
In conclusion, we present the first case of a profound lymphopenia in a newborn whose mother was treated with AZA during pregnancy, with 6-TGNs measurements and TPMT genotypes performed both in the newborn and in the mother.
The severity of the risk for the newborn due to the mother's treatment during pregnancy must be ascertained. Thus, the question arises whether a close follow-up of the pregnant woman should be performed, including TPMT phenotyping or genotyping [if not carried out at the beginning of the treatment] and TGN monitoring. If low TPMT activity is displayed and/or if TGN are high, the AZA dose should be lowered. At birth, we recommend a routine blood count for the newborn, to detect an eventual anaemia, thrombocytopenia or lymphopenia. Moreover, collaboration between gastroenterologists, obstetricians, and paediatricians is essential.
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